Cian Healthcare Limited IPO
(i) The Company was originally incorporated as “Cian Healthcare Private Limited” as a private limited Company on January 17, 2003.
(ii) The Company is a WHO-GMP & ISO -9001:2015 certified transnational manufacturing Company with a wide range of Pharmaceutical, Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness, and Food supplement products. The company complies with the standard manufacturing practices as laid down by the World Health Organization and is also certified by the Food and Drug Control Administration
(iii) The Company develops, manufactures and commercializes pharmaceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under 12 therapeutic segments :
[ Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Nutraceuticals]
Cian has developed more than 1,000 formulations and 2000 brands for the domestic market under above 12 divisions.
(iv) The Company also manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels, and Sachet. They have a special license for manufacturing veterinary products for the client like SAVAvet and Venky’s.
They had entered the International market in the year 2013-14 and are on regular basis exporting the products to various countries.
(v) They own and operate only one manufacturing facility situated at Roorkee, Uttarakhand. All of their products are manufactured at this facility only.
Objects of the Cian Healthcare Limited IPO:
Cian Healthcare Limited IPO Details:
Open Date: | May 02 2019 |
Close Date: | May 15 2019 |
Total Shares: | 6216000 |
Face Value: | ₹ 10 Per Equity Share |
Issue Type: | Book Buliding |
Issue Size: | 40 Cr. |
Lot Size: | 2000 Shares |
Issue Price: | ₹ 61-65 Per Equity Share |
Listing At: | BSE SME |
Listing Date: | May 17 2019 |
Promoters And Management:
Financials of Cian Healthcare Limited IPO:
Particulars(Lakh) | 2016 | 2017 | 2018 | 6MFY19 |
Balance Sheet Item | ||||
Share Capital | 140 | 140 | 140 | 1680 |
FV | 10 | 10 | 10 | 10 |
Net Worth | 1098.00 | 1329.00 | 1716.00 | 2226.00 |
Book Value | 78.43 | 94.93 | 122.57 | 13.25 |
Long-Term Debt | 2035.00 | 2399.00 | 2459.00 | 2476.00 |
Short-Term Debt | 1070.00 | 1567.00 | 2304.00 | 2049.00 |
D/E | 2.83 | 2.98 | 2.78 | 2.03 |
Receivables days | 94.00 | 96.00 | 156.00 | 263.00 |
P/L Items | ||||
Revenue | 4715.00 | 5185.00 | 5959.00 | 3301.00 |
EBITDA | 789 | 1001 | 1276 | 853 |
EBITDA Margins | 16.7% | 19.3% | 21.4% | 25.8% |
Profit | 154 | 231 | 387 | 398 |
PAT Margins | 3.3% | 4.5% | 6.5% | 12.1% |
EPS | 0.66 | 0.99 | 1.66 | 1.71 |
Comparison With Peers:
Particulars(Cr) | CIAN | Deccan | Zota |
Balance Sheet Item | |||
Share Capital | 1.4 | 13.5 | 17.54 |
FV | 10 | 10 | 10 |
Net Worth | 10.98 | 36.48 | 69.78 |
Book Value | 78.00 | 27.02 | 39.78 |
Long-Term Debt | 20.35 | 8.41 | 0.00 |
Short-Term Debt | 10.70 | 0.00 | 0.00 |
D/E | 2.83 | 0.23 | 0.00 |
P/L Items | |||
Revenue | 59.59 | 39.76 | 79.37 |
Revenue Growth in 3 years | 12.42% | 56.71% | 11.10% |
EBITDA | 12.76 | 15.45 | 12.9 |
EBITDA Growth in 3 years | 27.17% | 55.86% | 13.23% |
EBITDA Margins | 21.4% | 38.9% | 16.3% |
PAT | 3.87 | 12.68 | 7.27 |
PAT Growth in 3 years | 58.52% | 89.26% | 18.35% |
PAT Margins | 6.5% | 31.9% | 9.2% |
EPS | 1.66 | 9.70 | 4.23 |
Key Ratios and Valuation | |||
RONW | 35.2% | 34.8% | 10.4% |
P/E | 39 | 10.03 | 65.00 |
Mcap | 151.45 Cr | 158 Cr | 488 Cr |
Mcap/Sales | 2.54 | 3.97 | 6.15 |
Recommendation on Cian Healthcare Limited IPO:
Lead Manager of Cian Healthcare Limited IPO:
Registrar of Cian Healthcare Limited IPO:
Bid Details of Cian Healthcare Limited IPO as on
15 May 2019 | 06:00:00 PM
Category | No.of shares offered | No. of shares bid |
---|---|---|
2,950,000 | 5,642,000 | |
2,950,000 | 1,752,000 | |
316,000 | 316,000 | |
6,216,000 | 7,710,000 |
QIBs | Yes |
QIBs+HNIs Subscription | 1.91X |
Retail Subscription | 0.59X |
Total Subscription | 1.25X |
Discussion on Cian Healthcare Limited IPO:
Leave a Reply
You must be logged in to post a comment.